Back to Annual Report

A TasP First

This is the first time the made-in-BC TasP® strategy, and the related global 90-90-90 Target for the control of HIV/AIDS, will be applied to a non-infectious disease.

Last November, Diabetes Canada announced that it would be adapting the made-in-BC Treatment as Prevention®(TasP) strategy to diabetes to help make the more than six million Canadians living with pre-diabetes and diabetes aware of their status.

Adapting the TasP®strategy, and the related 90-90-90 Target, to diabetes will encourage early diagnosis, treatment and engagement into care to prevent diabetes-related complications that cost the Canadian health care system billions of dollars a year.

Developed by Dr. Julio Montaner, director, BC Centre of Excellence in HIV/AIDS (BC-CfE) at St. Paul’s Hospital, TasP and the 90-90-90 Target proposes to have at least 90 per cent of all people living with HIV diagnosed, at least 90 per cent of them on antiretroviral therapy and at least 90 per cent of them virologically suppressed by 2020.

Applied to prediabetes and diabetes, the 90-90-90 strategy would be implemented as follows:

  • 90 per cent of those diagnosed with prediabetes and diabetes (along with the 3.5 million Canadians who have already been diagnosed with diabetes) would receive treatment, lifestyle counseling or care to prevent or manage the disease.
  • 90 per cent of those receiving treatment would be seeing improved health indicators, such as lower three-month average blood glucose, with consequent improvements in blood pressure and lipids.

Read the full announcement here.